Kininogen 1 (KNG1) (N-Term) Peptide
Quick Overview for Kininogen 1 (KNG1) (N-Term) Peptide (ABIN2183947)
Target
Origin
Source
Application
-
-
Protein Region
- N-Term
-
Sequence
- ALKKYNSQNQ SNNQFVLYRI TEATKTVGSD TFYSFKYEIK EGDCPVQSGK
-
Characteristics
- This is a synthetic peptide designed for use in combination with anti-KNG1 Antibody. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
-
Purification
- Purified
-
-
-
-
Application Notes
- Optimal working dilution should be determined by the investigator.
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Reconstitution
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
-
Concentration
- 1 mg/mL
-
Buffer
- Final peptide concentration is 1 mg/mL in PBS.
-
Handling Advice
- Avoid repeat freeze-thaw cycles.
-
Storage
- -20 °C
-
Storage Comment
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
-
- KNG1 (Kininogen 1 (KNG1))
-
Background
-
Kininogens are inhibitors of thiol proteases. HMW-kininogen plays an important role in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII and inhibits the thrombin- and plasmin-induced aggregation of thrombocytes. The active peptide bradykinin that is released from HMW-kininogen shows a variety of physiological effects such as influence in smooth muscle contraction, induction of hypotension, natriuresis and diuresis, etc.
Alias Symbols: BDK, KNG
Protein Size: 391 -
Molecular Weight
- 43 kDa
-
Gene ID
- 3827
-
NCBI Accession
- NM_001166451, NP_001159923
-
UniProt
- C9JEX1
Target
-